Education
About Us
Working with TipRanks
Follow Us
Oruka Therapeutics (ORKA)
NASDAQ:ORKA
ORKA Stock Chart & Stats
$33.26
-$0.35(-1.84%)
At close: 4:00 PM EST
$33.26
-$0.35(-1.84%)
Day’s Range― - ―
52-Week Range$5.49 - $36.51
Previous CloseN/A
Volume71.58K
Average Volume (3M)530.53K
Market Cap
$1.59B
Enterprise Value$1.13B
Total Cash (Recent Filing)$349.15M
Total Debt (Recent Filing)$1.91M
Price to Earnings (P/E)―
Beta0.82
Next Earnings
Mar 05, 2026EPS Estimate
-0.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding48,409,233
10 Day Avg. Volume602,310
30 Day Avg. Volume530,527
Financial Highlights & Ratios
PEG Ratio-0.31
Price to Book (P/B)0.85
Price to Sales (P/S)0.00
P/FCF Ratio-5.61
Enterprise Value/Market Cap0.71
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-10.01
Forecast
1Y Price Target
$57.80Price Target Upside73.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial Adoption And Market PathwaysPhysician interest in at-home subcutaneous use and acceptance of clinic administration with buy-and-bill indicate flexible commercial pathways that could accelerate patient adoption across large psoriasis and psoriatic arthritis markets.
ORKA-002 Differentiation And Efficacy PotentialORKA-002's extended half-life and comparable peak exposure to a leading IL-17 therapy suggest the drug could deliver similar efficacy with much less frequent maintenance dosing, improving patient experience in psoriasis and hidradenitis suppurativa.
Pharmacokinetics And DosingExceptional half-life and sustained target inhibition for ORKA-001 support the potential for a once-year dosing regimen that could boost adherence and convenience versus current injectable therapies.
Bears Say
Cash Runway And Funding RiskLimited cash resources relative to spending increase the likelihood that the company will need to raise additional capital, which could constrain clinical progress or force reprioritization of programs.
Potential Shareholder DilutionThe need for future financing to support trials could result in equity dilution, reducing existing shareholders' ownership if new capital is issued.
Short Interest And Market SentimentNotable short interest signals investor skepticism and could amplify selling pressure and share volatility around upcoming clinical milestones or financing events.
Oruka Therapeutics News
ORKA FAQ
What was Oruka Therapeutics’s price range in the past 12 months?
Oruka Therapeutics lowest stock price was $5.49 and its highest was $36.51 in the past 12 months.
What is Oruka Therapeutics’s market cap?
Oruka Therapeutics’s market cap is $1.59B.
When is Oruka Therapeutics’s upcoming earnings report date?
Oruka Therapeutics’s upcoming earnings report date is Mar 05, 2026 which is in 20 days.
How were Oruka Therapeutics’s earnings last quarter?
Oruka Therapeutics released its earnings results on Nov 12, 2025. The company reported -$0.55 earnings per share for the quarter, beating the consensus estimate of -$0.577 by $0.027.
Is Oruka Therapeutics overvalued?
According to Wall Street analysts Oruka Therapeutics’s price is currently Undervalued.
Does Oruka Therapeutics pay dividends?
Oruka Therapeutics pays a Notavailable dividend of $19.356 which represents an annual dividend yield of N/A. See more information on Oruka Therapeutics dividends here
What is Oruka Therapeutics’s EPS estimate?
Oruka Therapeutics’s EPS estimate is -0.64.
How many shares outstanding does Oruka Therapeutics have?
Oruka Therapeutics has 48,409,233 shares outstanding.
What happened to Oruka Therapeutics’s price movement after its last earnings report?
Oruka Therapeutics reported an EPS of -$0.55 in its last earnings report, beating expectations of -$0.577. Following the earnings report the stock price went down -6.784%.
Which hedge fund is a major shareholder of Oruka Therapeutics?
Currently, no hedge funds are holding shares in ORKA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Oruka Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$57.80 (73.78% Upside)
$57.80 (73.78% Upside)
Hedge Fund Trend
Increased
By 4.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 2.8%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-4.61%
12-Months-Change
Fundamentals
Return on Equity
-23.05%
Trailing 12-Months
Asset Growth
956.07%
Trailing 12-Months
Company Description
Oruka Therapeutics
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
ORKA Stock 12 Month Forecast
Average Price Target
$57.80
▲(73.78% Upside)
Technical Analysis
Verastem
―
AnaptysBio
―
Compass Therapeutics
―
Olema Pharmaceuticals
―
Bicara Therapeutics Inc.
―
Ownership Overview
16.65% Insiders
16.50% Mutual Funds
0.98% Other Institutional Investors
57.81% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---